ArticlePharmacoEconomics2026

The Opportunity Cost of Funding High-Cost Biologics in the Context of Inequitable Access to the Fundamentals of Care: An External Assessment Group Perspective.

Julia Whitehall et al.PubMed ↗Publisher ↗

No numbers read from the abstract.